IL161418A0 - Direct targeting binding proteins - Google Patents
Direct targeting binding proteinsInfo
- Publication number
- IL161418A0 IL161418A0 IL16141802A IL16141802A IL161418A0 IL 161418 A0 IL161418 A0 IL 161418A0 IL 16141802 A IL16141802 A IL 16141802A IL 16141802 A IL16141802 A IL 16141802A IL 161418 A0 IL161418 A0 IL 161418A0
- Authority
- IL
- Israel
- Prior art keywords
- binding proteins
- direct targeting
- targeting binding
- direct
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32883501P | 2001-10-15 | 2001-10-15 | |
US34188101P | 2001-12-21 | 2001-12-21 | |
US34564102P | 2002-01-08 | 2002-01-08 | |
US40491902P | 2002-08-22 | 2002-08-22 | |
PCT/US2002/032718 WO2003033654A2 (fr) | 2001-10-15 | 2002-10-15 | Proteines de liaison de ciblage direct |
Publications (1)
Publication Number | Publication Date |
---|---|
IL161418A0 true IL161418A0 (en) | 2004-09-27 |
Family
ID=27502389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16141802A IL161418A0 (en) | 2001-10-15 | 2002-10-15 | Direct targeting binding proteins |
Country Status (11)
Country | Link |
---|---|
US (1) | US20030148409A1 (fr) |
EP (1) | EP1448780A4 (fr) |
JP (1) | JP2005507659A (fr) |
KR (1) | KR20050036875A (fr) |
CN (1) | CN1604966A (fr) |
BR (1) | BR0213303A (fr) |
CA (1) | CA2463672A1 (fr) |
IL (1) | IL161418A0 (fr) |
MX (1) | MXPA04003535A (fr) |
PL (1) | PL374495A1 (fr) |
WO (1) | WO2003033654A2 (fr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7696325B2 (en) * | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
RU2408606C2 (ru) | 2000-10-20 | 2011-01-10 | Тугаи Сейяку Кабусики Кайся | Соединение - агонист тро |
EP2351838A1 (fr) * | 2000-10-20 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Anticorps agonistiques qui réticuler |
JP4303105B2 (ja) * | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
WO2004058821A2 (fr) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Ligand |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
JP4643255B2 (ja) * | 2002-06-10 | 2011-03-02 | バクシネックス インコーポレーティッド | 乳癌および膀胱癌において差次的に発現される遺伝子ならびにコードされるポリペプチド |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
ATE328906T1 (de) * | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US20090217404A1 (en) * | 2002-09-27 | 2009-08-27 | Lowe Scott W | Cell-based RNA interference and related methods and compositions |
EP1561759B9 (fr) * | 2002-10-11 | 2009-08-26 | Chugai Seiyaku Kabushiki Kaisha | Agent inducteur de la mort cellulaire |
US20090186839A1 (en) * | 2003-02-17 | 2009-07-23 | Cold Spring Harbor Laboratory | Model for studying the role of genes in chemoresistance |
US20060294604A1 (en) * | 2003-02-17 | 2006-12-28 | Fridman Jordan S | Model for studying the role of genes in tumor resistance to chemotherapy |
JP2004279086A (ja) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | 放射線画像変換パネル及び放射線画像変換パネルの製造方法 |
EP1609803A4 (fr) * | 2003-03-31 | 2006-05-24 | Chugai Pharmaceutical Co Ltd | Anticorps modifie dirige contre cd22 et son utilisation |
AU2004232928A1 (en) * | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
EP2829283B1 (fr) | 2003-04-30 | 2017-06-07 | Universität Zürich | Procédés permettant de traiter le cancer à l'aide d'une immunotoxine |
NZ568403A (en) | 2003-05-09 | 2009-10-30 | Univ Duke | CD20-specific antibodies and methods of employing same |
AU2004296184B2 (en) * | 2003-12-04 | 2010-12-16 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
EP1712565A4 (fr) * | 2003-12-12 | 2009-03-11 | Chugai Pharmaceutical Co Ltd | Agents induisant la mort cellulaire |
JPWO2005056602A1 (ja) * | 2003-12-12 | 2008-03-06 | 中外製薬株式会社 | アゴニスト活性を有する改変抗体のスクリーニング方法 |
US20080274110A1 (en) * | 2004-04-09 | 2008-11-06 | Shuji Ozaki | Cell Death-Inducing Agents |
US8137907B2 (en) * | 2005-01-03 | 2012-03-20 | Cold Spring Harbor Laboratory | Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof |
US20060280738A1 (en) * | 2005-06-08 | 2006-12-14 | Tedder Thomas F | Anti-CD19 antibody therapy for transplantation |
KR101335798B1 (ko) * | 2005-02-15 | 2013-12-02 | 듀크 유니버시티 | 항-cd19 항체 및 종양학에서 이의 용도 |
US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
BRPI0607486B8 (pt) | 2005-03-03 | 2021-05-25 | Immunomedics Inc | anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos. |
EP1870458B1 (fr) | 2005-03-31 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | ISOMERES STRUCTURELS sc(Fv)2 |
KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
JP3989936B2 (ja) * | 2005-04-07 | 2007-10-10 | 進 須永 | 抗腫瘍剤及び新規dnアーゼ |
JP5047947B2 (ja) * | 2005-05-05 | 2012-10-10 | デューク ユニバーシティ | 自己免疫疾患のための抗cd19抗体治療 |
WO2006123724A1 (fr) * | 2005-05-18 | 2006-11-23 | The University Of Tokushima | Nouvel agent pharmaceutique a base d’un anticorps anti-hla |
CA2610265A1 (fr) | 2005-05-31 | 2007-05-10 | Cold Spring Harbor Laboratory | Methode de production de micro-arns |
WO2006132363A1 (fr) | 2005-06-10 | 2006-12-14 | Chugai Seiyaku Kabushiki Kaisha | Stabilisant pour une préparation de protéine contenant de la méglumine et son utilisation |
KR101360671B1 (ko) | 2005-06-10 | 2014-02-07 | 추가이 세이야쿠 가부시키가이샤 | sc(Fv)2를 함유하는 의약조성물 |
JP5224580B2 (ja) * | 2005-06-10 | 2013-07-03 | 中外製薬株式会社 | sc(Fv)2部位特異的変異体 |
WO2007063308A2 (fr) * | 2005-12-01 | 2007-06-07 | Domantis Limited | Formats d'anticorps a domaine non competitif qui lient le recepteur type 1 d'interleukine 1 |
EP2674440B1 (fr) | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Ensembles bioactifs à base d'immunoglobuline multivalent |
EP4218801A3 (fr) * | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Procédé de modification d'anticorps pour purifier un anticorps bispécifique |
WO2007145227A1 (fr) * | 2006-06-14 | 2007-12-21 | Chugai Seiyaku Kabushiki Kaisha | Promoteur de la prolifération des cellules souches hématopoïétiques |
AU2007261247A1 (en) * | 2006-06-22 | 2007-12-27 | Vaccinex, Inc. | Anti-C35 antibodies for treating cancer |
US20100150927A1 (en) * | 2006-07-13 | 2010-06-17 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducer |
MX2009002414A (es) | 2006-09-08 | 2009-05-20 | Medimmune Llc | Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria. |
CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
US8877186B2 (en) * | 2007-06-06 | 2014-11-04 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
BRPI0814060A2 (pt) * | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
AU2008341050B2 (en) | 2007-12-26 | 2013-10-24 | Vaccinex, Inc. | Anti-C35 antibody combination therapies and methods |
PT3912643T (pt) * | 2009-02-13 | 2023-01-12 | Immunomedics Inc | Imunoconjugados com uma ligação intracelular clivável |
US20110293629A1 (en) | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
AU2014331494A1 (en) | 2013-10-02 | 2016-04-07 | Viventia Bio Inc. | Anti-EpCAM antibodies and methods of use |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
WO2016132366A1 (fr) | 2015-02-18 | 2016-08-25 | Enlivex Therapeutics Ltd. | Association d'une immunothérapie et d'une thérapie de contrôle des cytokines pour le traitement du cancer |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US10583198B2 (en) | 2015-03-12 | 2020-03-10 | Viventia Bio Inc. | Dosing strategies for targeting EPCAM positive bladder cancer |
US10576163B2 (en) | 2015-03-12 | 2020-03-03 | Viventia Bio Inc. | Methods of treatment for EpCAM positive bladder cancer |
CN107708811B (zh) | 2015-04-21 | 2021-04-30 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
EP3398965A4 (fr) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Procédé pour favoriser l'efficacité de purification d'un polypeptide contenant une région fc |
US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
CN113144292B (zh) * | 2021-03-11 | 2021-12-21 | 苏州大学 | 干细胞分泌物及其制备方法、生物活性骨水泥及制备方法和应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444744A (en) * | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
DE3008260A1 (de) * | 1980-03-04 | 1981-09-17 | Siemens AG, 1000 Berlin und 8000 München | Verfahren zum aufzeichnen von stroemungsgrenzschichten in fluessigen medien |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5567610A (en) * | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5229275A (en) * | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US6027725A (en) * | 1991-11-25 | 2000-02-22 | Enzon, Inc. | Multivalent antigen-binding proteins |
CA2131528C (fr) * | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Agents diagnostiques et/ou therapeutiques cibles pour les cellules endotheliales neovasculaires |
US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
SG41929A1 (en) * | 1992-09-25 | 1997-08-15 | Commw Scient Ind Res Org | Target binding polypeptide |
EP0672142B1 (fr) * | 1992-12-04 | 2001-02-28 | Medical Research Council | Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation |
AU675268B2 (en) * | 1992-12-10 | 1997-01-30 | Celltech Limited | Humanised antibodies directed against A33 antigen |
US5861156A (en) * | 1993-01-08 | 1999-01-19 | Creative Biomolecules | Methods of delivering agents to target cells |
ATE267610T1 (de) * | 1996-03-20 | 2004-06-15 | Immunomedics Inc | Glykosylierte igg antikörper |
AU717020B2 (en) * | 1996-05-03 | 2000-03-16 | Immunomedics Inc. | Targeted combination immunotherapy of cancer |
US5968869A (en) * | 1997-06-03 | 1999-10-19 | Celanese International Corporation | Vinyl acetate catalyst comprising palladium and gold deposited on a copper containing carrier |
JP4926320B2 (ja) * | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfの選択的阻害による癌処置のための組成物および方法 |
CN1675245B (zh) * | 2002-06-14 | 2011-01-12 | 免疫医疗公司 | 人源化单克隆抗体hPAM4 |
-
2002
- 2002-10-15 PL PL02374495A patent/PL374495A1/xx unknown
- 2002-10-15 IL IL16141802A patent/IL161418A0/xx unknown
- 2002-10-15 CN CNA028250680A patent/CN1604966A/zh active Pending
- 2002-10-15 CA CA002463672A patent/CA2463672A1/fr not_active Abandoned
- 2002-10-15 KR KR1020047005693A patent/KR20050036875A/ko not_active Application Discontinuation
- 2002-10-15 WO PCT/US2002/032718 patent/WO2003033654A2/fr not_active Application Discontinuation
- 2002-10-15 MX MXPA04003535A patent/MXPA04003535A/es not_active Application Discontinuation
- 2002-10-15 JP JP2003536384A patent/JP2005507659A/ja not_active Withdrawn
- 2002-10-15 EP EP02782156A patent/EP1448780A4/fr not_active Withdrawn
- 2002-10-15 US US10/270,073 patent/US20030148409A1/en not_active Abandoned
- 2002-10-15 BR BR0213303-2A patent/BR0213303A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2005507659A (ja) | 2005-03-24 |
MXPA04003535A (es) | 2005-06-20 |
EP1448780A4 (fr) | 2005-08-31 |
WO2003033654A2 (fr) | 2003-04-24 |
US20030148409A1 (en) | 2003-08-07 |
CN1604966A (zh) | 2005-04-06 |
PL374495A1 (en) | 2005-10-31 |
BR0213303A (pt) | 2005-06-07 |
CA2463672A1 (fr) | 2003-04-24 |
KR20050036875A (ko) | 2005-04-20 |
WO2003033654A3 (fr) | 2003-11-13 |
EP1448780A2 (fr) | 2004-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL161418A0 (en) | Direct targeting binding proteins | |
IL202255A0 (en) | Binding domain-immunoglobulin fusion proteins | |
EP1365022A4 (fr) | Proteine associee a l'adiponectine | |
GB0130557D0 (en) | Proteins | |
GB0130720D0 (en) | Proteins | |
EP1437410A4 (fr) | Nouvelles proteines contenant de la selenocysteine | |
GB0105402D0 (en) | Novel proteins | |
GB0119446D0 (en) | Binding proteins | |
EP1373306A4 (fr) | Proteines associees au cytoskeleton | |
AU2002326909A8 (en) | Neurotransmission-associated proteins | |
GB0130560D0 (en) | Proteins | |
GB0126888D0 (en) | Binding protein | |
GB0100750D0 (en) | Novel proteins | |
GB0105401D0 (en) | Novel proteins | |
GB0106318D0 (en) | Protein | |
GB0128487D0 (en) | Proteins | |
GB0120557D0 (en) | Proteins | |
GB0125514D0 (en) | Proteins | |
GB0128374D0 (en) | Proteins | |
GB0130718D0 (en) | Proteins | |
GB0128596D0 (en) | Proteins | |
GB0130719D0 (en) | Proteins | |
GB0130739D0 (en) | Proteins | |
GB0130742D0 (en) | Proteins | |
GB0111303D0 (en) | Proteins |